Filter by:
Topic
Resource Type
Display Only
Showing 22 Results
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Stakeholders Find Step Therapy Should Be Evidence-Based, Flexible and Transparent: Assessing Appropriateness Using a Consensus Approach
Stakeholders disagree on when step therapy is appropriate, but agree on a set of criteria about how to develop, implement, communicate, safeguard and evaluate step therapy protocols.
If You Must Do Step Therapy, Do It Right
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Supporting Value-Based Purchasing Through Changes in Medicaid Best Price
In a recent column for PharmaBoardroom, Michael Ciarametaro, vice president for research at the National Pharmaceutical Council, elaborated on the ways in which MBP presents a barrier to creative…
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
Are Value-based Arrangements the Answer We’ve Been Waiting for?
This NPC study explored the use of value-based arrangements as a mechanism for cost containment in the United States, noting the strengths and limitations of these tools.
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…
Value-Based Agreements May Be More Prevalent Than Assumed
As the US health care system continues to transition from volume to value, NPC/Duke-Margolis research shows that value-based agreements between payers and biopharmaceutical manufacturers may be more…
Value-Based Agreements May Be More Prevalent Than Assumed
Research published in AJMC shows that value-based agreements (VBAs) between U.S. payers and biopharmaceutical manufacturers may be more prevalent than originally thought.
NPC in Specialty Pharmacy Times: Health Care Economic Information and Its Impact on Value-Based Contracts
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains how expanding HCEI for sophisticated audiences like payers and population health…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
NPC in Chain Drug Review: Pharmacy Outlook 2018
NPC President Dan Leonard explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more in his latest commentary for Chain Drug Review.
Opportunities and Challenges With Value-Based Contracting
In his commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard explores the challenges and opportunities in implementing value-based contracts.
Learn More About Oncology Clinical Pathways in Webinar from Turning the Tide Against Cancer
Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit…
AMCP Partnership Forum on Value in Oncology Proceedings Published in JMCP
The Journal of Managed Care & Specialty Pharmacy this week published the proceedings from the Academy of Managed Care Pharmacy partnership forum, “Driving Value and Outcomes in Oncology,” which…
Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing
A study convened an expert roundtable of patient, payer, and employer representatives to review four case studies to understand when it would be more (or less) acceptable to require patients with the…
Using an Electronic Medication Refill System to Improve Provider Productivity in an Accountable Care Setting
This case study highlights the critical components of Sharp Rees-Stealy Medical Group's electronic medication refill system that allows for a centralized team to manage all incoming prescription…